{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-25-069706","form_type":"8-K","ticker":"HURA","cik":"0001498382","company_name":"TuHURA Biosciences, Inc./NV","filed_at":"2025-04-01T23:59:59+00:00","discovered_at":"2026-05-14T18:02:48.485542+00:00","generated_at":"2026-05-24T00:43:10.877981+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"confidence":"high","headline":"TuHURA reports FY2024 R&D $13.3M, cash through late Q4 2025; Phase 3 trial to start Q2","bullets":["Full-year 2024 R&D expense $13.3M (up from $9.4M); G&A $4.3M (vs $4.1M prior year).","Raised $36M in 2024; cash expected to fund operations through late Q4 2025.","Phase 3 IFx-2.0 trial for MCC under SPA with FDA; enrollment targeted Q2 2025 (partial clinical hold on CMC).","Acquisition of Kineta's VISTA antibody KVA12123 targeted to close Q2 2025.","2025 milestones include Phase 2 VISTA trial in AML; novel bi-specific ADC platform advancing."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-25-069706","json":"https://secwatch.observer/filing/0001193125-25-069706.json","markdown":"https://secwatch.observer/filing/0001193125-25-069706.md","text":"https://secwatch.observer/filing/0001193125-25-069706.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1498382/000119312525069706/0001193125-25-069706-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1498382/000119312525069706/d888264d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-24T00:43:10.877981+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}